Search
Catalyst Pharmaceuticals Inc
CPRXAdd to Watchlist
31.490USD
0.0000.00%
Close 07-14 16:00（ET）Quotes delayed by 15 min
3.85BMarket Cap
17.43P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-14The current earnings forecast score of Catalyst Pharmaceuticals Inc is 6.67, ranking 126 out of 156 in the Pharmaceuticals industry. The average price target is 34.00, with a high of 40.00 and a low of 32.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
33.542
Target Price
+6.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Catalyst Pharmaceuticals Inc
CPRX
4
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Catalyst Pharmaceuticals Inc's expected revenue for the next quarter?
Catalyst Pharmaceuticals Inc's expected revenue is 156.31M.
What is Catalyst Pharmaceuticals Inc's price target?
Analysts forecast that Catalyst Pharmaceuticals Inc's price target is USD 34.00, with the highest forecast at USD 40.00 and the lowest forecast at USD 32.00.
How have Catalyst Pharmaceuticals IncCPRX's recent earnings per share performed?
The market expectation was USD 0.52, while Catalyst Pharmaceuticals IncCPRX's earnings per share (EPS) for the previous quarter was USD 0.43. EPS for the next quarter is expected at USD 0.48.
What is the analyst rating for Catalyst Pharmaceuticals Inc?
Based on the ratings of Catalyst Pharmaceuticals Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.